Literature DB >> 18597839

Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)?

Stephen P Glasser1, Mary Cushman, Ronald Prineas, Dawn Kleindorfer, Valerie Prince, Zhiying You, Virginia J Howard, George Howard.   

Abstract

CONTEXT: Aspirin use may reduce the risk of stroke and coronary heart disease. Differential use for vascular prophylaxis may contribute to racial and geographic disparities in stroke and coronary heart disease morbidity or mortality.
OBJECTIVE: To assess the prevalence and predictors of aspirin use for primary prophylaxis of stroke in the general population free of clinically diagnosed stroke or coronary heart disease. DESIGN AND
SETTING: Cross-sectional analysis of 16,908 participants (age 45 or greater), from a population-based national cohort study (REasons for Geographic And Racial Differences in Stroke) enrolled from February 2003-August 2006 with oversampling from the southeastern Stroke Belt and African Americans. Individuals with a prior stroke or coronary heart disease, or regular use of aspirin for pain relief were excluded from analyses. MAIN OUTCOME MEASURES: Aspirin use and reasons for use were assessed using a computer-assisted telephone interview.
RESULTS: Prophylactic aspirin use was substantially higher among whites (34.7%) than African Americans (27.2%; p<0.0001). There was a higher prevalence of aspirin use for prophylaxis in the Stroke Belt (32.1%) than in the rest of the nation (30.8%; p=0.07). After adjustment for measures of socio-economic status, the odds ratio of aspirin use in the rest of the nation compared to Stroke Belt was 0.90 (95% CI 0.84-0.97). There was a higher likelihood of prophylactic aspirin use among participants who were white, male, older, past cigarette smokers, or of higher socio-economic status (higher income or education).
CONCLUSIONS: In this study, aspirin use to prevent stroke and coronary heart disease was higher among whites than African Americans, raising the possibility that differential aspirin use could contribute to the racial disparities in vascular disease mortality. Counter to our hypothesis, aspirin use was more common in the Stroke Belt than the rest of the country, so differential aspirin use in the Stroke Belt is unlikely to contribute to geographic disparities in stroke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18597839      PMCID: PMC2556126          DOI: 10.1016/j.ypmed.2008.05.009

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  16 in total

1.  Probability of stroke: a risk profile from the Framingham Study.

Authors:  P A Wolf; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1991-03       Impact factor: 7.914

2.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

Authors:  R B D'Agostino; S Grundy; L M Sullivan; P Wilson
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

3.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

4.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

5.  Aspirin use for the primary prevention of coronary heart disease in older adults.

Authors:  Nicolas Rodondi; Eric Vittinghoff; Jacques Cornuz; Javed Butler; Jingzhong Ding; Suzanne Satterfield; Anne B Newman; Tamara B Harris; Stephen B Hulley; Douglas C Bauer
Journal:  Am J Med       Date:  2005-11       Impact factor: 4.965

6.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

7.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

8.  Stroke in a biracial population: the excess burden of stroke among blacks.

Authors:  Brett Kissela; Alexander Schneider; Dawn Kleindorfer; Jane Khoury; Rosemary Miller; Kathleen Alwell; Daniel Woo; Jerzy Szaflarski; James Gebel; Charles Moomaw; Arthur Pancioli; Edward Jauch; Rakesh Shukla; Joseph Broderick
Journal:  Stroke       Date:  2004-02       Impact factor: 7.914

9.  Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study.

Authors:  R B D'Agostino; P A Wolf; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

Review 10.  Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  E Shahar; A R Folsom; F J Romm; K M Bisgard; P A Metcalf; L Crum; P G McGovern; R G Hutchinson; G Heiss
Journal:  Am Heart J       Date:  1996-05       Impact factor: 4.749

View more
  12 in total

Review 1.  Ancel Keys Lecture: Adventures (and misadventures) in understanding (and reducing) disparities in stroke mortality.

Authors:  George Howard
Journal:  Stroke       Date:  2013-09-12       Impact factor: 7.914

Review 2.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

3.  Ethnic and geographic variation in stroke mortality trends.

Authors:  Richard F Gillum; John Kwagyan; Thomas O Obisesan
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

4.  Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs.

Authors:  Jeremy R Van't Hof; Sue Duval; Jeffrey R Misialek; Niki C Oldenburg; Clarence Jones; Milton Eder; Russell V Luepker
Journal:  J Community Health       Date:  2019-06

5.  Adverse housing and neighborhood conditions and inflammatory markers among middle-aged African Americans.

Authors:  Mario Schootman; Elena M Andresen; Fredric D Wolinsky; Theodore K Malmstrom; John E Morley; Douglas K Miller
Journal:  J Urban Health       Date:  2010-03       Impact factor: 3.671

6.  Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.

Authors:  Greer A Burkholder; Ashutosh R Tamhane; Jorge L Salinas; Michael J Mugavero; James L Raper; Andrew O Westfall; Michael S Saag; James H Willig
Journal:  Clin Infect Dis       Date:  2012-08-31       Impact factor: 9.079

7.  Primary prophylactic aspirin use and incident stroke: reasons for geographic and racial differences in stroke study.

Authors:  Stephen P Glasser; Martha K Hovater; Daniel T Lackland; Mary Cushman; George Howard; Virginia J Howard
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-04-06       Impact factor: 2.136

8.  Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study.

Authors:  Lena Mathews; Dingfen Han; Michele K Evans; Alan B Zonderman; Chiadi E Ndumele; Deidra C Crews
Journal:  J Racial Ethn Health Disparities       Date:  2021-02-16

9.  Racial and geographic variation in coronary heart disease mortality trends.

Authors:  Richard F Gillum; Alem Mehari; Bryan Curry; Thomas O Obisesan
Journal:  BMC Public Health       Date:  2012-06-06       Impact factor: 3.295

10.  Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance.

Authors:  Gregory A Roth; Catherine W Gillespie; Ali A Mokdad; Danny D Shen; David W Fleming; Andy Stergachis; Christopher J L Murray; Ali H Mokdad
Journal:  BMC Cardiovasc Disord       Date:  2014-02-07       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.